Operating
Unrealized gain (loss) on debt and equity securities, net
ResMed Unrealized gain (loss) on debt and equity securities, net decreased by 63.7% to -$10.13M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 79.4%, from -$5.65M to -$10.13M. Over 2 years (FY 2022 to FY 2025), Unrealized gain (loss) on debt and equity securities, net shows an upward trend with a -8.1% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
First reportedQ1 2021
Last reportedQ3 2026Apr 30, 2026
Metric ID:
operating_debt_and_equity_securities_unrealized_gain_lossHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.61M | -$4.4M | -$1.74M | -$11.68M | -$3.28M | $8.37M | $6.42M | -$602K | -$1.89M | $13.92M | -$15.47M | -$680K | -$1.44M | -$5.65M | -$2.53M | -$6.19M | -$10.13M |
| QoQ Change | — | -178.5% | +60.6% | -572.9% | +71.9% | +355.1% | -23.3% | -109.4% | -213.8% | +836.9% | -211.2% | +95.6% | -111.6% | -292.4% | +55.1% | -144.3% | -63.7% |
| YoY Change | — | — | — | — | -158.4% | +290.0% | +469.9% | +81.6% | -122.6% | +116.9% | — | -13.0% | +23.8% | -140.6% | +83.6% | -810.3% | -79.4% |
Range-$15.47M – $13.92M
CAGR+15.9%
Avg YoY Growth-21.5%
Median YoY Growth+5.4%
Current Streak2 quarters decline
Frequently Asked Questions
- What is ResMed's unrealized gain (loss) on debt and equity securities, net?
- ResMed (RMD) reported unrealized gain (loss) on debt and equity securities, net of -$10.13M in Q1 2026.
- How has ResMed's unrealized gain (loss) on debt and equity securities, net changed year-over-year?
- ResMed's unrealized gain (loss) on debt and equity securities, net decreased by 79.4% year-over-year, from -$5.65M to -$10.13M.
- What is the long-term trend for ResMed's unrealized gain (loss) on debt and equity securities, net?
- Over 2 years (2022 to 2025), ResMed's unrealized gain (loss) on debt and equity securities, net has grown at a -8.1% compound annual growth rate (CAGR), from -$12.2M to -$10.3M.